July 28, 2014 6:21 AM ET

Health Care Technology

Company Overview of Favrille Inc.

Company Overview

As of January 27, 2009, Favrille Inc. was acquired by MyMedicalRecords, Inc., in a reverse merger transaction. Favrille, Inc., a biopharmaceutical company, engages in the development and commercialization of immunotherapies for the treatment of cancer and other diseases of the immune system. Its principal product candidate includes Specifid, a following rituxan induction therapy that is in phase III trial for the treatment of B-cell non-hodgkin’s lymphoma (NHL); a following rituxan induction therapy, which is in phase II trial for treating -naive or relapsed or refractory follicular B-cell NHL patients; a single therapeutic agent in relapsed or refractory NHL patients that is in phase II cli...

10421 Pacific Center Court

San Diego, CA 92121

United States

Founded in 2000

3 Employees





Key Executives for Favrille Inc.

Favrille Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
NorthPoint Domain Inc. United States
LifeCare, Inc. United States
LifeDox, Inc. United States
Inbox Health LLC United States
Neurotronics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Favrille Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.